Xenetic Biosciences, Inc.
(NASDAQ : XBIO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.22%196.961.2%$506.18m
GILDGilead Sciences, Inc.
-0.54%73.190.9%$444.63m
BIIBBiogen Inc.
-0.53%329.181.3%$366.64m
CELGCelgene Corporation
-0.29%82.341.2%$329.49m
ILMNIllumina, Inc.
-1.79%315.933.5%$285.25m
REGNRegeneron Pharmaceuticals, Inc.
-1.82%377.162.6%$219.86m
ALXNAlexion Pharmaceuticals, Inc.
0.17%122.152.0%$209.10m
VRTXVertex Pharmaceuticals Incorporated
-1.22%179.101.9%$200.99m
SRPTSarepta Therapeutics, Inc.
1.02%131.8416.4%$168.13m
AAgilent Technologies, Inc.
-0.33%66.021.5%$154.03m
BMRNBioMarin Pharmaceutical Inc.
0.80%100.314.4%$129.38m
LGNDLigand Pharmaceuticals Incorporated
-1.02%200.5223.3%$107.04m
VKTXViking Therapeutics, Inc.
-2.14%14.150.9%$106.43m
NKTRNektar Therapeutics
0.37%49.095.6%$105.85m
EXASExact Sciences Corporation
-1.77%66.0325.3%$96.40m

Company Profile

Xenetic Biosciences, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of next generation biologic drugs and novel orphan oncology therapeutics. Its lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod), which focuses on the treatment of progesterone resistant endometrial cancer. It also offers proprietary drug development platform, PolyXen, which enables next-generation biologic drugs by improving their half-life and other pharmacological properties. The company was founded on August 9, 2011 and is headquartered in Lexington, MA.